Expert Insights

At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Nicole Lamanna, MD, discusses the potential for the use of non-covalent BTK inhibitor pirtobrutinib in treatment regimens for patients with chronic lymphocytic leukemia.

Benjamin Tomlinson, MD, explains the course of treatment he selected for a 49-year-old patient with myelodysplastic syndrome with isolated deletion of 5q.

At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Neil E. Kay, MD, discusses the pathobiology and management of double refractory CLL.

Andrew Zelenetz, MD, discusses up and coming treatment developments on the horizon within the large-cell lymphoma research space, focusing on the importance of immunotherapy.

Andrew Zelenetz, MD, shares study results that suggest sequential rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) induction followed by rituximab, ifosfamide, carboplatin, and etoposide ([R]-ICE) consolidation...

At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Ajai Chari, MD, University of California – San Francisco, San Francisco, California, discusses the role of bispecific antibodies in the treatment of patients with multiple...

At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Ajai Chari, MD, evaluates the potential value of measurable residual disease as a predictive variable for multiple myeloma.

Komal Jhaveri, MD, discusses results from the CAPItello-291 study, which led to the FDA approval of capivasertib plus fulvestrant for HR-positive, HER2-negative, advanced breast cancer harboring one or more PIK3CA/AKT1/PTEN alterations.

At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Ajai Chari, MD, shares his insights on the role of CD38 monoclonal antibodies and bispecific antibodies for the treatment of patients with multiple myeloma.

In this video, a panel of experts highlight 8-year updated results from the APHINITY trial and reflect on the progress that has been made in the setting of HER2-positive breast cancer.